Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and cabozantinib

erlotinib hydrochloride has been researched along with cabozantinib in 6 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(cabozantinib)		Trials
(cabozantinib)		Recent Studies (post-2010) (cabozantinib)
4,3537863,033731127716

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)cabozantinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)1.118
High affinity nerve growth factor receptorHomo sapiens (human)0.0723
Acyl-CoA desaturase 1Rattus norvegicus (Norway rat)0.0013
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.1699
Hepatocyte growth factor receptorHomo sapiens (human)0.0791
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0108
Fibroblast growth factor receptor 1Homo sapiens (human)0.0113
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.178
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.012
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.5617
Kinesin-1 heavy chainHomo sapiens (human)0.19
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.006
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.3151
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.8877
Angiopoietin-1 receptorHomo sapiens (human)0.0143
Macrophage-stimulating protein receptorHomo sapiens (human)0.069
Coiled-coil domain-containing protein 6Homo sapiens (human)0.4615
SAFB-like transcription modulatorHomo sapiens (human)0.0013

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW1
Alden, RS; Awad, MM; Bahcall, M; Jaklitsch, MT; Jänne, PA; Kim, ND; Kuang, Y; Lydon, CA; Oxnard, GR; Patel, JD; Paweletz, CP; Sacher, AG; Sholl, LM; Sim, T1
Aisner, SC; Bowden, M; Carbone, DP; Dahlberg, SE; Gerstner, GJ; Huang, Y; Khalid, AA; Lerner, RE; Neal, JW; Owonikoko, TK; Ramalingam, SS; Rubin, JL; Steen, PD; Stella, PJ; Wakelee, HA1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A1
Engelman, J; Gettinger, S; Jänne, PA; Lara, PN; Leach, J; Miles, DR; Subramaniam, DS; Wakelee, HA; Wax, M; West, H; Yaron, Y1
Hu, Y; Jia, LJ; Li, T; Zhang, J1

Reviews

2 review(s) available for erlotinib hydrochloride and cabozantinib

ArticleYear
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
    Cancer, 2013, May-15, Volume: 119, Issue:10

    Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation

2013
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    European urology, 2017, Volume: 71, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017

Trials

2 trial(s) available for erlotinib hydrochloride and cabozantinib

ArticleYear
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:12

    Topics: Aged; Anilides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines

2016
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyridines; Treatment Outcome

2017

Other Studies

2 other study(ies) available for erlotinib hydrochloride and cabozantinib

ArticleYear
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
    Cancer discovery, 2016, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Treatment Outcome

2016
[Acute Myocardial Infarction and Purpuric Drug Eruption Caused by Erlotinib Combined with Cabozantinib:Report of One Case].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2019, Apr-28, Volume: 41, Issue:2

    Topics: Anilides; Drug Eruptions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Myocardial Infarction; Pyridines

2019